|Salary:||from £21,000 per annum|
|Placed On:||10th November 2021|
|Closes:||28th November 2021|
Applicants should send a detailed CV and cover letter to email@example.com.
If no cover letter is received with your application, your application will not be considered.
Oncimmune is searching for an enthusiastic and ambitious individual to join a high performing team working on the development and manufacture of in vitro diagnostic devices in the fields of oncology and infectious diseases (COVID-19) based in the Oncimmune labs in Nottingham, UK.
This is an exciting opportunity for someone who is passionate about working in a high-performing, fast-paced environment at the forefront of cancer and COVID-19 research. The successful candidate will support the workflow of critical projects and product manufacture, having an immediate impact within a fast-growing company.
Laboratory related activities include but not limited to:
Experience & qualifications
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. With a partnership led approach, Oncimmune is evolving and leveraging its technology with global pharmaceutical and biotechnology companies, early-stage start-ups, leading academic groups, and not-for-profit companies.
ImmunoINSIGHTS is Oncimmune’s service to the life science industry, built off the company’s proprietary autoantibody profiling technology. Underpinned by Oncimmune’s proprietary high throughput immunogenic protein library, one of the largest in the world, more than 95% of human antigens can be utilised for profiling autoantibodies in patients receiving or about to receive treatment. The unique combination of Oncimmune’s core technology and understanding of the immune system enables life-science organisations to optimise drug development, leading to more effective, targeted as well as safer treatments for patients.
The key to improving cancer survival is early detection and optimal selection for therapy. As a company, we are driven by our passion to improve cancer survival and give people 'extra time'. Oncimmune's immunodiagnostic blood test, EarlyCDT Lung, can detect and help identify lung cancer on average four years earlier than standard clinical diagnosis. With over 200,000 tests already performed for patients worldwide, and its use being supported by peer reviewed data in over 12,000 patients, EarlyCDT Lung is poised to become an integral part of future lung cancer detection programmes, globally.
Type / Role: